3 unchanged sentences
Based upon information supplied from our transfer agent, there were approximately 810 shareholders of record of our Common Stock as of February 23, 2024.
+Added: We have not paid any dividends since our inception and do not anticipate declaring or paying any cash dividends on our Common Stock in the foreseeable future.
+Added: Payment of future dividends, if any, will be at the discretion of our Board of Directors and will depend on many factors, including general economic and business conditions, our strategic plans, our financial results and condition, legal requirements and other factors as our Board deems relevant.
Stock Performance Graph
−Removed: The following graph compares the cumulative total stockholder return on our Common Stock with the cumulative total stockholder return of the Nasdaq Composite Index, the Nasdaq Biotechnology Index and the Russell 2000 Index, assuming an investment of $100.00 on December 31, 2017.
+Added: The following graph compares the cumulative total stockholder return on our Common Stock with the cumulative total s tockholder return of the Nasdaq Composite Index and the Russell 2000 Index, for the five year period that commenced on December 31, 2018 and ended December 31, 2023, assuming an investment of $100.00 on December 31, 2018.
ASSUMES $100 INVESTED ON DEC.
2 unchanged sentences
FISCAL YEAR ENDED DEC.
−Removed: Change in Comparison Index
−Removed: During 2022, we changed our Cumulative Total Return comparison from the Nasdaq Biotechnology Index to the Russell 2000 Index.
−Removed: The Russell 2000 Index, which includes the Company’s common stock, is a stock index consisting of 2000 publicly-traded small-cap companies.
−Removed: We use the Russell 2000 for peer benchmarking in certain compensation arrangements with certain of our employees.
−Removed: We believe the Russell 2000 provides more meaningful information than the Nasdaq Biotechnology Index because the breadth of the latter index contains significant diversity in market capitalization, stage of clinical development, total addressable markets, and other factors.
−Removed: The Company’s common stock is not included on the Nasdaq Biotechnology Index.
Securities Authorized for Issuance Under Equity Compensation Plans
1 unchanged sentence
Recent Sales of Unregistered Securities
+Added: On December 22, 2023, all 95,000 outstanding shares of the Company’s Series B Convertible Preferred Stock (the “ Preferred Stock ”), together with accrued dividends, were mandatorily converted into shares of the Company’s Common Stock in accordance with the Preferred Stock terms set forth in the Company’s Articles of Incorporation, as amended.
+Added: T he Preferred Stock conversion, triggered by the Company’s increased Common Stock share price and following the third anniversary of the Preferred Stock financing transaction in July of 2020.
+Added: As a result of this conversion, 29,761,650 new shares of Common Stock were issued by the Company to an affiliate of EW Healthcare Partners and to certain funds managed by Hayfin Capital Management LLP.
+Added: The Company received no consideration upon the conversion.
+Added: The shares of Common Stock issued pursuant to the conversion of the Preferred Stock were issued in reliance upon exemptions pursuant to Section 3(a)(9) under the Securities Act of 1933, as amended, and pursuant to applicable state securities laws and regulations, in that the shares of Common Stock were issued by the Company to its existing security holders and no commission or other remuneration was paid or given directly or indirectly for soliciting such exchange.
Purchases of Equity Securities by the Issuer and Affiliated Purchasers
−Removed: The following table sets forth information regarding the purchases of the Company’s equity securities made by or on behalf of the Company or any affiliated purchaser (as defined in Rule 10b-18 under the Exchange Act) during the three-month period ended December 31, 2022.
−Removed: Period Total Number of
−Removed: Shares Purchased Average Price Paid
−Removed: per Share Total Number of Shares Purchased as Part of Publicly Announced Plans
−Removed: or Programs Approximate Dollar Value of Shares that May Yet Be Purchased Under Plans or Programs
−Removed: October 1, 2022 - October 31, 2022 — $ — — $ —
−Removed: November 1, 2022 - November 30, 2022 — $ — — $ —
−Removed: December 1, 2022 - December 31, 2022 — $ — — $ —
−Removed: Total for the quarter — $ — — $ —
+Added: There were no purchases of our Common Stock made by or on behalf of the Company during the year ended December 31, 2023.
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.